Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer

Inclusion Criteria

• •For inclusion in the study, subjects must fulfil all of the following criteria:
• •1. . Signed and dated informed consent indicating that the patient (or legally acceptable representative) has been informed of all the pertinent aspects of the trial prior to enrollment.
• •2. . Invasive breast cancer confirmed by histology or cytology with the tumor complete resection.
• •3. . Patients without remote organs metastasis.
• •4. . The Ages of patients ≥ 18 years and ≤70 years.
• •5. . Patients with positive axillary lymph nodes, or negative axillary lymph nodes plus one of these conditions: Triple-negative breast cancer, HER- 2(+),Ki-67≥15%.
• •6. . The values of aspartate aminotransferase(AST),alanine aminotransferase(ALT), alkaline phosphatase(ALP), total bilirubin(TBIL), UREA, CREA were less than 2 times of upper limits of normal at the beginning of aromatase inhibitors（AIs） therapy.
• •7. . TOP2α is available to be detected in the primary tumour tissue.
• •8. . Patients received the regimens of anthracyclines followed Taxanes or containing no Taxanes non-dose dense chemotherapy suggested by the guidelines of National Comprehensive Cancer Network （NCCN) 2014.